Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRatasark Summarten_US
dc.contributor.authorPak Thaichanaen_US
dc.contributor.authorJutharat Supanen_US
dc.contributor.authorPuttinan Meepowpanen_US
dc.contributor.authorT. Randall Leeen_US
dc.contributor.authorWirote Tuntiwechapikulen_US
dc.description.abstract© 2020 American Chemical Society. Perylene diimide (PDI) derivatives have been studied as G-quadruplex ligands that suppress telomerase activity by facilitating G-quadruplex formation of telomeric DNA and the hTERT promoter. PIPER, the prototypical PDI, reduces telomerase activity in lung and prostate cancer cells, leading to telomere shortening and cellular senescence of these cells. However, PIPER suffers from poor hydrosolubility and the propensity to aggregate at neutral pH. In this report, we synthesized a new asymmetric PDI, aPDI-PHis, which maintains one N-ethyl piperidine side chain of PIPER and has histidine as another side chain. The results show that aPDI-PHis is superior to its symmetric counterparts, PIPER and PDI-His, in terms of hydrosolubility, G-quadruplex binding, cellular uptake, and telomerase inhibition in prostate cancer cells. These results suggest that one N-ethyl piperidine side chain of PDI is sufficient for G-quadruplex binding, while another side chain can be tuned to elicit desirable properties. These findings might lead to better PDIs for use as anticancer drugs.en_US
dc.subjectChemical Engineeringen_US
dc.titleSuperiority of an asymmetric perylene diimide in terms of hydrosolubility, G‑quadruplex binding, cellular uptake, and telomerase inhibition in prostate cancer cellsen_US
article.title.sourcetitleACS Omegaen_US
article.volume5en_US of Houstonen_US Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.